Caladrius Biosciences Inc (CLBS) was Upgraded by H.C. Wainwright to ” Buy” and the brokerage firm has set the Price Target at $1.25. Earlier the firm had a rating of “Neutral ” on the company shares. H.C. Wainwright advised their investors in a research report released on Apr 29, 2016.
Caladrius Biosciences Inc opened for trading at $0.7 and hit $0.7099 on the upside on Wednesday, eventually ending the session at $0.7, with a gain of 1.45% or 0.01 points. The heightened volatility saw the trading volume jump to 83,874 shares. Company has a market cap of $41 M.
In a different news, on Aug 18, 2015, David J Mazzo (CEO) purchased 20,000 shares at $1.40 per share price. According to the SEC, on Aug 13, 2015, Robert S Vaters (CFO) purchased 12,385 shares at $1.35 per share price.
Caladrius Biosciences Inc. formerly NeoStem Inc. is a clinical-stage biopharmaceutical company. The Company’s clinical program is based on its dendritic cell and cancer cell technology. It is focused on the development of a cancer treatment designed to focus the cells responsible for tumor growth and metastasis known as cancer or tumor initiating cells (CSCs). Its lead product candidate based on this platform technology is NBS20 (targeted cancer immunotherapy) which is in Phase II trials focuses on malignant melanoma as an initial indication. Its therapeutic platforms also include ischemic repair (CD34 Cell Program) and immune modulation (T Regulatory Cell Program). Its CD34 Cell Program develops therapies designed to address diseases and conditions caused by ischemia. Its product candidate in CD34 Cell Program is NBS10 which has completed Phase I clinical trials. Under T Regulatory Cell Program the Company is developing NBS03D which is in the Phase I clinical trial stage.